Brief: Innate Pharma Provides Update On Lacutamab Clinical Programme

Innate Pharma SA

05/10/2023 06:03

Oct 5 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA PROVIDES UPDATE ON LACUTAMAB CLINICAL
PROGRAM
    * PHASE 2 TELLOMAK TRIAL FULLY RECRUITED, FINAL DATA
EXPECTED Q4
2023
    * PHASE 1B PTCL TRIAL AWAITING FUTILITY INTERIM ANALYSIS,
PRELIMINARY DATA EXPECTED Q4 2023
    * US FDA PLACES LACUTAMAB IND ON PARTIAL CLINICAL HOLD FOR
NEW
PATIENT ENROLLMENT FOLLOWING ONE UNEXPECTED SEVERE ADVERSE
REACTION
    * PATIENTS ALREADY ON STUDY TREATMENT WHO ARE DERIVING
CLINICAL
BENEFIT MAY CONTINUE TREATMENT AFTER BEING RECONSENTED
    * TELLOMAK, INNATE PHARMA'S ONGOING PHASE 2 TRIAL OF
LACUTAMAB IN
CUTANEOUS T-CELL LYMPHOMA (CTCL), COMPLETED ENROLLMENT IN Q2
2023

Source text for Eikon:  ID:nBw98tbcMa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))